EKG Findings in Psychiatric Practice: QT Prolongation, Drug Interactions, and Clinical Monitoring

1. Where Psychiatry and Cardiology Overlap: A History of Sudden Cardiac Deaths

The intersection of psychiatry and cardiology is not new. For decades, psychiatrists prescribed medications with known cardiac effects without systematic cardiac monitoring. In 1963, thioridazine became the first antipsychotic to receive FDA black box warning for QT prolongation. Numerous cases documented sudden cardiac death in thioridazine-treated patients, often occurring after dose escalation or abrupt medication discontinuation (paradoxically, withdrawal of QT-prolonging drugs can sometimes unmask lethal torsades de pointes). Thioridazine remains notorious for its cardiac risk, yet continued to be prescribed widely because alternatives were limited.

In the 1990s and 2000s, droperidol (an intravenous antipsychotic used in emergency departments and ICUs) was linked to sudden cardiac deaths. The FDA issued a black box warning in 2001 after reports of fatal arrhythmias, even though droperidol was often used in single low doses. This warning paradoxically created access challenges for anesthesiology and emergency medicine, which had used droperidol effectively for decades with careful monitoring, yet the cardiac risk prompted widespread restriction.

As newer antipsychotics (second-generation agents) gained FDA approval in the 1990s–2000s, clinicians expected improved cardiac safety. However, ziprasidone (approved 2001) was demonstrated to prolong QTc interval in dose-dependent manner. Similarly, haloperidol, long considered "safe" by comparison to first-generation drugs, was found to carry significant QT prolongation risk when administered intravenously at high doses. Citalopram (the most prescribed antidepressant in the United States), was found to dose-dependently prolong QTc, prompting FDA dosage restrictions (40 mg/day maximum for most patients; 20 mg/day for age ≥60 years or those with liver disease) in 2011.

These historical episodes underscored a critical insight: psychiatric medications across multiple drug classes (antipsychotics, antidepressants, mood stabilizers, and others) can affect cardiac repolarization, and without adequate EKG monitoring and clinical risk stratification, psychiatrists unknowingly exposed patients to sudden cardiac death risk. Contemporary psychiatric practice now emphasizes QTc monitoring for high-risk medications and patients, yet many prescribers remain inadequately trained in EKG interpretation and risk assessment.

Why Psychiatrists Need EKG Literacy

EKG literacy is essential for psychiatrists because: (1) Many psychiatric medications carry cardiac risks that manifest on EKG before clinical symptoms; (2) Risk factors for drug-induced arrhythmias (female sex, electrolyte abnormalities, structural heart disease, drug interactions) are common in psychiatric populations; (3) Early recognition of QTc prolongation or other EKG abnormalities can prevent sudden cardiac death; (4) Cardiology consultation, when indicated, requires psychiatrists to communicate EKG findings clearly and understand cardiologists' recommendations; (5) Informed consent discussions about psychiatric medications should include realistic discussion of cardiac risks based on individual patient factors.

2. EKG Basics for Psychiatrists: Waves, Intervals, and Interpretation

The 12-Lead EKG: Anatomy and Electrode Placement

A standard 12-lead EKG records electrical activity from 12 different perspectives of the heart: 6 precordial (chest) leads (V1–V6) and 6 limb leads (I, II, III, aVR, aVL, aVF). The precordial leads are placed across the anterior chest wall in a standardized pattern: V1 (4th intercostal space at right sternal border), V2 (4th intercostal space at left sternal border), V3 (midway between V2 and V4), V4 (5th intercostal space at midclavicular line), V5 (anterior axillary line at 5th intercostal), V6 (midaxillary line at 5th intercostal). Limb leads are derived from electrodes on the arms and legs using mathematical calculations.

For psychiatrists, understanding the standard format is sufficient: each lead represents electrical activity from a specific cardiac region, and abnormalities localize to the region represented by that lead. For example, ST elevation in leads II, III, aVF suggests inferior myocardial infarction; ST elevation in V1–V4 suggests anterior infarction.

Cardiac Waves and Their Meaning

P Wave: Represents atrial depolarization (electrical activation of the atria). Normal P wave duration is <120 ms (0.12 seconds) and amplitude <2.5 mm in limb leads. Abnormal P waves (tall peaked, prolonged, biphasic) suggest atrial pathology.

QRS Complex: Represents ventricular depolarization. The QRS interval (duration) normally is <120 ms (<0.12 seconds). Each component: Q wave = initial negative deflection, R wave = initial positive deflection, S wave = negative deflection after R wave. (A lead may not have all three components.) Wide QRS complexes (≥120 ms) suggest bundle branch blocks, ventricular rhythms, or drug effects (e.g., tricyclic antidepressants at toxic doses).

T Wave: Represents ventricular repolarization. T waves are normally upright in most leads (except aVR, sometimes V1). T-wave abnormalities (inversion, flattening, prolonged duration) can indicate ischemia, electrolyte imbalance (notably hypokalemia with prominent U wave), or drug effects.

U Wave: A small positive deflection that follows the T wave; represents repolarization of the ventricular conduction system. Prominent U waves are characteristic of hypokalemia and can be seen with QT-prolonging drugs.

Critical Intervals and Their Normal Values

PR Interval: Measured from the beginning of the P wave to the beginning of the QRS. Normal range: 120–200 ms (0.12–0.20 seconds). Represents atrial depolarization plus AV node conduction delay. Prolonged PR interval (>200 ms) indicates first-degree AV block; progressive prolongation with dropped beats = second-degree AV block.

QRS Duration: Measured from the beginning of the Q wave to the end of the S wave. Normal: <120 ms (<0.12 seconds). A QRS ≥120 ms indicates bundle branch block or ventricular dysrhythmia. Drugs like tricyclic antidepressants, antipsychotics, and other antimuscarinic agents can widen the QRS, particularly at high doses or in overdose.

QT Interval: Measured from the beginning of the QRS to the end of the T wave (including U waves if prominent). This interval represents the entire ventricular depolarization and repolarization cycle. The QT interval varies with heart rate (faster heart rate = shorter QT). To standardize, the QTc (corrected QT) is calculated using Bazett formula: QTc = QT / √(RR interval in seconds). Normal QTc: <450 ms in men, <460 ms in women. QTc >500 ms is considered severely prolonged and carries high arrhythmia risk.

Rate and Rhythm Assessment

Rate: Normal sinus rate is 60–100 bpm at rest. Tachycardia (>100 bpm) or bradycardia (<60 bpm) can be seen with psychiatric medications. Clozapine and tricyclic antidepressants commonly cause tachycardia; lithium and cholinesterase inhibitors cause bradycardia.

Rhythm: Normal rhythm is regular sinus rhythm with each QRS preceded by a P wave at consistent intervals. Irregular rhythms (atrial fibrillation, premature beats, AV blocks) should be identified and characterized. Psychiatric medications rarely cause primary arrhythmias but can precipitate them in susceptible patients.

Axis Assessment Basics

The QRS axis represents the overall direction of ventricular depolarization in the frontal plane. Normal axis is -30° to +90° (estimated by examining leads I and aVF: if both are positive, axis is normal). Right axis deviation (RAD) occurs when the axis is >+90°; left axis deviation (LAD) is <-30°. Extreme axis deviation (>180° to -90°, called "north-west" axis) is rare and seen in very specific conditions including tricyclic antidepressant overdose, emphysema, and lateral MI. RAD is nonspecific and can be seen with chronic lung disease, left ventricular hypertrophy, or simply normal variation in body habitus.

3. Underlying Cardiac Electrophysiology: Ion Channels and Action Potentials

Cardiac Ion Channels and Depolarization/Repolarization

The heartbeat is generated by orchestrated movement of ions (sodium Na+, potassium K+, and calcium Ca2+) across the cardiac myocyte membrane. Specialized ion channels open and close in sequence, allowing these ions to flow down their electrochemical gradients. This ionic flow generates the electrical activity that propagates across the heart and triggers mechanical contraction.

Sodium Channels: Fast sodium channels are responsible for rapid depolarization (phase 0 of the action potential). These channels open when the cell is at rest, allowing Na+ to rush into the cell. Drugs like tricyclic antidepressants block these channels, slowing depolarization and widening the QRS.

Potassium Channels: Delayed rectifier potassium channels (particularly the rapidly activating IKr channel, also called hERG channel after the human ether-a-go-go-related gene) are the primary repolarizing current. These channels open late in the action potential and allow K+ to leave the cell, restoring negative charge and terminating the action potential. Blockade of these channels prolongs action potential duration and QT interval.

Calcium Channels: L-type calcium channels are responsible for the plateau phase of the ventricular action potential. Some psychiatric medications weakly affect calcium channels, contributing to conduction effects.

The Cardiac Action Potential and Five Phases

Phase 0 (Depolarization): Rapid influx of sodium through fast Na+ channels, causing the membrane potential to rapidly depolarize from -90 mV toward +30 mV. This phase corresponds to the QRS on EKG. Drugs blocking sodium channels (e.g., tricyclics) slow this phase, widening QRS.

Phase 1 (Early Repolarization): Sodium channels inactivate, and early potassium currents activate, beginning to restore negative charge.

Phase 2 (Plateau): Calcium influx balances potassium efflux, maintaining a plateau at +20 mV. This prolonged plateau phase (0.1–0.3 seconds) is unique to cardiac muscle and is essential for coordinated contraction.

Phase 3 (Repolarization): Calcium channels inactivate, and delayed rectifier potassium currents (hERG, IKr) dominate, causing rapid repolarization back toward -90 mV. This phase corresponds to the T wave on EKG. Blockade of hERG/IKr channels slows repolarization, prolonging phase 3 and the QT interval.

Phase 4 (Resting Potential): The cell rests at -90 mV, maintained by Na+/K+ ATPase and active potassium influx.

hERG Potassium Channel Blockade: The Common Mechanism for Drug-Induced QT Prolongation

The hERG potassium channel (encoded by the human ether-a-go-go-related gene) is responsible for the rapidly activating delayed rectifier current (IKr), which is essential for normal repolarization. Importantly, the hERG channel is a common pharmacological target for many unrelated drug classes. Antipsychotics, antidepressants, antiarrhythmics, antihistamines, antibiotics, antifungals, antiretrovirals, and even some antiemetics block hERG channels.

When a drug blocks hERG channels, repolarization slows, the action potential duration lengthens, and the QT interval on EKG prolongs. If multiple drugs that block hERG are used concurrently (polypharmacy), or if the patient has underlying risk factors that compromise repolarization reserve (female sex, electrolyte abnormalities, bradycardia, structural heart disease), the risk of dangerous arrhythmias (torsades de pointes) increases markedly. Understanding which psychiatric medications block hERG is essential for risk stratification.

The Concept of Repolarization Reserve

Healthy hearts have inherent "repolarization reserve"—a safety margin that allows the heart to tolerate some degree of potassium channel blockade without manifest QT prolongation or arrhythmia. This reserve is maintained by redundancy in repolarizing currents and appropriate autonomic tone. However, certain conditions deplete repolarization reserve: female sex (hormonal effects on ion channels), hypokalemia (reduces potassium gradient, slowing repolarization), hypomagnesemia (required for proper channel function), bradycardia (longer diastolic intervals allow more drug binding), structural heart disease (myocardial hypertrophy, fibrosis, or scarring alters electrophysiology), and interactions with other QT-prolonging drugs. When repolarization reserve is compromised, even modest hERG blockade from a single psychiatric medication can precipitate life-threatening arrhythmias.

4. QTc Prolongation: The Most Important EKG Finding in Psychiatry

Which Psychiatric Medications Prolong QTc?

Torsades de Pointes: Mechanism and Mortality Risk

Torsades de pointes ("twisting of the points") is a polymorphic ventricular tachycardia characterized by QRS complexes that appear to twist around the baseline. It is a consequence of prolonged QT interval and early afterdepolarizations (EADs), abnormal electrical activity that occurs during phase 2–3 of the action potential, often triggered by premature beats in the setting of prolonged repolarization.

The mechanism: In the setting of QT prolongation, the relative refractory period (when the cardiac tissue is partially excitable) extends into the T wave. A premature atrial or ventricular beat occurring on the T wave (vulnerable period) can trigger an EAD and initiate torsades. Once initiated, torsades typically degenerates into ventricular fibrillation (VF), causing sudden cardiac arrest and death if not immediately treated with defibrillation.

Key risk factors for torsades in the setting of QT prolongation include: (1) Female sex (female hormones prolong action potential duration and QT); (2) Bradycardia (longer diastolic intervals allow more drug binding to ion channels and more prolongation); (3) Electrolyte abnormalities, especially hypokalemia and hypomagnesemia; (4) Structural heart disease (myocardial infarction, cardiomyopathy, hypertrophy); (5) Renal or hepatic impairment (prolongs drug metabolism and clearance); (6) Drug interactions (concurrent QT-prolonging agents); (7) Recent initiation or dose increase of QT-prolonging medication.

Notably, torsades can occur suddenly and without warning, even in patients whose QTc is only modestly prolonged (>450–500 ms). Patients may report palpitations, syncope, or dyspnea before collapse. Mortality if torsades degenerates to VF without prompt defibrillation is >50%.

Tisdale Risk Score: Stratifying QT Prolongation Risk

The Tisdale Risk Score is a validated clinical tool that quantifies the risk of drug-induced QT prolongation in hospitalized patients. While originally developed for inpatient use, its principles apply to all psychiatric settings. The score integrates patient factors and medication factors to estimate risk.

Scoring System (simplified): Points are awarded for: (1) Age ≥68 years (1 pt); (2) Female sex (1 pt); (3) Hypokalemia (3 pts if <3.0 mEq/L, 1 pt if 3.0–3.5 mEq/L); (4) Hypomagnesemia (2 pts if <1.7 mg/dL); (5) Baseline QTc ≥450 ms (2 pts); (6) Hepatic cirrhosis (1 pt); (7) Heart failure (1 pt); (8) Acute myocardial infarction (2 pts); (9) Use of diuretics (1 pt); (10) Specific QT-prolonging medications (1–3 pts depending on drug); (11) Multiple QT-prolonging medications (3 pts for ≥2 drugs). Total risk interpretation: <6 points = low risk (<1% incidence of QT prolongation), 6–10 points = moderate risk (2–5% incidence), >10 points = high risk (>5% incidence, up to 10% with highest scores).

For psychiatrists, the value of Tisdale scoring is identifying high-risk patients (particularly those with female sex, older age, hypokalemia, low baseline QTc, or on multiple QT-prolonging drugs) who warrant baseline EKG, frequent monitoring, and often alternative medication selection.

Monitoring Guidelines and Baseline EKG Indications

Baseline EKG is recommended for patients starting:

• Thioridazine (mandatory before initiation)
• Ziprasidone (at high-risk doses or in vulnerable patients)
• Haloperidol IV (mandatory before high-dose IV use)
• Paliperidone or iloperidone (recommended)
• Citalopram or escitalopram (if dose >20 mg/day or age ≥60 years)
• Tricyclic antidepressants (if dose >100 mg/day or in older adults)
• Methadone (recommended before treatment)
• Any patient with baseline risk factors (female sex, older age, hypokalemia, bradycardia, structural heart disease, family history of sudden cardiac death)

Monitoring Frequency: After baseline EKG, follow-up EKGs are typically obtained at: (1) 1 week after medication initiation (peak drug levels reached); (2) 1 month after initiation (equilibrium reached); (3) After any dose increase; (4) Annually for patients on stable high-risk medications; (5) More frequently if QTc is borderline (450–500 ms) or if additional QT-prolonging drugs are added; (6) Urgently if the patient develops palpitations, syncope, or dyspnea.

Risk Factors for QT Prolongation in Psychiatric Patients

When QTc Is >500 ms: Management Decisions

QTc >500 ms is considered severely prolonged and carries high arrhythmia risk. Management options:

1. Discontinue the offending medication: If QTc rises to >500 ms, the highest-risk QT-prolonging drug should be discontinued if clinically tolerable. Alternative medications with lower cardiac risk should be selected.

2. Aggressive electrolyte repletion: If hypokalemia or hypomagnesemia coexist, these must be corrected. Target potassium >4.0 mEq/L and magnesium >2.0 mg/dL in this setting. Repletion often reduces QTc by 30–50 ms.

3. Remove other QT-prolonging medications: If the patient is on multiple QT-prolonging drugs (e.g., ziprasidone + citalopram), discontinue or switch one to a cardiologically safer alternative.

4. Optimize heart rate and hemodynamics: If the patient has bradycardia, assess for causes (hypothyroidism, beta-blockers, cardiac disease) and treat as appropriate. A slower heart rate prolongs repolarization; mild tachycardia can shorten QT.

5. Cardiology referral: Consider urgent cardiology consultation if QTc is severely prolonged (>550 ms), if symptoms suggest arrhythmia (palpitations, syncope), or if the clinical situation is complex (multiple comorbidities, polypharmacy, prior arrhythmias).

6. Telemetry monitoring: In inpatient settings, continuous cardiac monitoring is indicated for QTc >500 ms, especially if risk factors are present.

5. Other EKG Findings in Psychiatric Practice

Sinus Tachycardia

Resting heart rate >100 bpm is a common EKG finding in psychiatric patients, particularly those on:

• Clozapine: Tachycardia in 25% of patients; mechanism unclear but related to alpha-adrenergic antagonism; usually persists but is benign if asymptomatic
• Tricyclic antidepressants: Anticholinergic-mediated tachycardia; worsened by orthostatic hypotension
• Stimulant medications: Amphetamines, methylphenidate; sympathomimetic effects; risk increases with doses and in vulnerable patients
• Selective serotonin reuptake inhibitors: Occasionally cause tachycardia, possibly through 5-HT1A effects on autonomic tone

Management: Tachycardia alone (without symptoms or underlying cardiac disease) is usually not an indication to discontinue medication. Assess for underlying causes (anxiety, pain, infection, hyperthyroidism, dehydration). If the patient is symptomatic (palpitations, dyspnea, chest pain), evaluate with EKG, troponin, and possibly echocardiography to rule out structural disease.

Sinus Bradycardia

Resting heart rate <60 bpm is less common in psychiatric populations but can occur with:

• Lithium: Bradycardia in ~10–20% of patients; mechanism unclear; may reflect direct cardiac effects or TSH elevation (hypothyroidism)
• Cholinesterase inhibitors: Used for cognitive enhancement; cholinergic effects increase vagal tone
• Beta-blockers: Sometimes used for anxiety or tremor control

Management: Asymptomatic bradycardia (e.g., HR 55 bpm) in healthy young adults may be physiologic. However, if bradycardia is symptomatic (dizziness, dyspnea, syncope) or if the rate is very slow (<50 bpm), evaluate for causes: check TSH (lithium-induced hypothyroidism), assess for cardiac disease (obtain troponin, echocardiogram if concerned), and consider reducing the offending drug or adding a chronotropic agent (theophylline, isoproterenol) if medication continuation is essential.

T-Wave Abnormalities

Lithium: Classic EKG finding with lithium is diffuse T-wave flattening or inversion, often accompanied by PR and QTc prolongation. The T-wave changes are usually benign and reversible upon lithium discontinuation. However, some patients on long-term lithium develop persistent T-wave changes even after discontinuation, raising concern for direct myocardial effects. Baseline EKG is reasonable for patients starting lithium; annual or biennial EKGs are reasonable for long-term lithium users.

Other causes of T-wave abnormalities: Electrolyte abnormalities (hypokalemia causes prominent U waves and T-wave depression), myocardial ischemia or infarction, pulmonary embolism, CNS events (subarachnoid hemorrhage can cause dramatic "cerebral T waves"—deep T-wave inversions in multiple leads), ventricular hypertrophy.

Brugada-Like Pattern

Brugada syndrome is a genetic disorder of sodium channel function that predisposes to sudden cardiac death. The EKG shows characteristic "coved" ST elevation in leads V1–V2, followed by negative T waves. Some psychiatric medications can produce Brugada-like EKG patterns without underlying Brugada syndrome:

• Tricyclic antidepressants: Particularly at high doses; sodium channel blockade mimics Brugada pattern
• Lithium: Can accentuate ST changes
• Antipsychotics: Rarely reported with haloperidol

Clinical significance: A newly appearing Brugada pattern in a patient starting a psychiatric medication (especially TCAs) warrants discontinuation and cardiology evaluation to distinguish drug-induced pattern from underlying Brugada syndrome (genetic form carries sudden death risk).

AV Conduction Delays and Bundle Branch Blocks

First-degree AV block (PR >200 ms): Can occur with antipsychotics, antidepressants (especially TCAs), and lithium. Usually asymptomatic and benign; does not require medication discontinuation if asymptomatic.

Second-degree AV block (progressive PR prolongation with occasional dropped beats, or fixed 2:1 conduction): Rare with psychiatric medications but reported with antipsychotics and TCAs, particularly at high doses. Requires cardiac evaluation and possible pacemaker consideration if symptomatic.

Bundle branch blocks (QRS ≥120 ms): Can be seen with TCAs and antipsychotics at high doses. Right bundle branch block (RBBB) pattern is more common than left bundle branch block (LBBB). If newly appearing during psychiatric medication treatment, obtain baseline comparison EKGs and assess for progression. If symptomatic (syncope, dyspnea), cardiology evaluation is warranted.

ST-Segment Changes

ST elevation or depression can reflect myocardial ischemia, infarction, pericarditis, or in some cases, psychiatric medication effects. Clozapine, in rare cases (incidence ~0.01%), can cause myocarditis in the first weeks of treatment; myocarditis presents with chest pain, troponin elevation, and often ST changes. Any new ST changes warrant troponin, CK-MB, and cardiology evaluation to rule out acute coronary syndrome or myocarditis.

EKG Findings in Eating Disorders

Patients with anorexia nervosa (especially severe, long-standing cases) present with characteristic EKG abnormalities reflecting severe malnutrition and electrolyte depletion:

• Bradycardia: Often marked (resting HR 40–50 bpm), reflecting severe metabolic suppression; usually reverses with nutritional rehabilitation
• Low voltage: Low amplitude QRS and T waves across all leads, reflecting myocardial atrophy from malnutrition
• Prolonged QT: From electrolyte abnormalities (hypokalemia, hypomagnesemia, hypophosphatemia)
• Prominent U waves: Signature of hypokalemia
• ST depression and T-wave flattening
• Nonspecific ST-T changes

Clinical pearls: These EKG changes are often reversible with nutritional rehabilitation and electrolyte repletion, yet they carry arrhythmia risk during refeeding (refeeding syndrome can cause fatal arrhythmias). Psychiatric patients with eating disorders require baseline EKG, electrolyte monitoring, and cautious nutritional rehabilitation. Adding any QT-prolonging psychiatric medication in the context of anorexia nervosa significantly elevates torsades risk.

EKG Signature of Tricyclic Antidepressant Overdose

TCA overdose produces a characteristic EKG pattern that is pathognomonic and diagnostically important:

• Wide QRS complex: QRS ≥120 ms or even >200 ms in severe overdose; reflects massive sodium channel blockade
• Prolonged PR interval: From AV node depression
• Prolonged QT interval: From potassium channel effects
• Right axis deviation (RAD): QRS axis shifts rightward, often >90°
• Terminal R wave in aVR: A prominent R wave (or R') in lead aVR (which normally shows only a small r wave) is characteristic and sometimes called "aVR sign" of TCA toxicity; reflects delayed depolarization of the right ventricular outflow tract
• Sinus tachycardia or dysrhythmias: Ventricular ectopy common in severe overdose

Recognition of this pattern (especially the combination of wide QRS + RAD + aVR R wave) in an unconscious patient can immediately raise suspicion of TCA overdose and prompt life-saving interventions (sodium bicarbonate therapy to narrow QRS, seizure prophylaxis, intensive care monitoring for arrhythmias).

6. When to Order EKGs and Clinical Decision-Making Framework

Baseline EKG: Systematic Approach

Monitoring Frequency After Baseline EKG

High-Risk Patients (QTc >450–480 ms at baseline, or QTc <450 ms but Tisdale score >10):

• Repeat EKG at 1 week after medication initiation
• Repeat EKG at 4 weeks after initiation
• Repeat EKG after any dose increase
• Annual EKGs while on stable high-risk medication
• Repeat EKG if additional QT-prolonging drug is added
• Urgent EKG if patient develops palpitations, syncope, or dyspnea

Moderate-Risk Patients (Tisdale 6–10, or on moderate-risk QT drugs like ziprasidone at standard doses):

• Repeat EKG at 4 weeks after initiation
• Repeat EKG after significant dose increases
• Biennial EKGs (every 2 years) while on stable medication

Lower-Risk Patients (Tisdale <6, on low-risk drugs like aripiprazole or sertraline):

• Baseline EKG optional (obtain if any risk factors present)
• Routine follow-up EKGs not necessary unless clinical change
• Annual EKGs if patient age >65 or female with additional risk factors

Cardiology Consultation Indications

Refer to cardiology if:

• QTc >500 ms
• QTc >480 ms plus symptoms (palpitations, syncope, dyspnea)
• New bundle branch block or second-degree AV block on psychiatric medication
• Troponin elevation or chest pain (possible myocarditis or acute coronary syndrome)
• Suspected arrhythmia (palpitations, syncope, documented dysrhythmia)
• Pre-existing cardiac disease and need to start high-risk psychotropic medication
• Eating disorder with EKG abnormalities and planned psychiatric treatment
• Complex polypharmacy with multiple QT-prolonging drugs

Clinical Decision-Making Framework: Integrating Risk and Benefit

Step 1: Assess the Patient's Cardiac Risk Profile

Calculate or estimate Tisdale score. Identify risk factors: age, sex, electrolyte status, baseline QTc, structural heart disease, renal/hepatic function, baseline heart rate.

Step 2: Identify the Psychiatric Indication and Select Medication

For a given psychiatric condition (e.g., first-episode schizophrenia), identify the appropriate medication class and specific agents. Rank medications by efficacy and cardiac safety. Example: For first-episode schizophrenia, aripiprazole or risperidone are excellent first-line choices with low cardiac risk; if these fail, consider higher-risk agents (ziprasidone, paliperidone) only if benefit justifies risk.

Step 3: Obtain Baseline EKG if Indicated

Based on medication, patient age/sex, and risk factors, obtain baseline EKG. Measure QTc using standard Bazett formula (ideally manually, as automated measurements can be inaccurate). If QTc >460 ms (women) or >450 ms (men), reassess whether the planned medication is appropriate or whether a lower-risk alternative exists.

Step 4: Optimize Modifiable Risk Factors

Check electrolytes (especially potassium and magnesium). Correct any abnormalities before initiating QT-prolonging medication. If the patient has bradycardia, investigate causes and optimize as appropriate. Advise patient on avoiding other QT-prolonging medications (over-the-counter antihistamines, certain antibiotics).

Step 5: Titrate the Medication and Monitor

Initiate medication at standard starting dose and titrate per guidelines. Schedule follow-up EKG at 1–4 weeks depending on risk profile. Educate patient on warning symptoms (palpitations, syncope, dyspnea) and provide clear instructions to seek immediate care if symptoms develop.

Step 6: Interpret Follow-Up EKGs and Make Adjustments

If follow-up QTc is normal (<450 ms men, <460 ms women), continue medication as tolerated. If QTc is borderline (450–480 ms), continue monitoring closely and consider dose reduction or alternative drug if other risk factors emerge. If QTc is >480 ms and rising, or if QTc >500 ms, discontinue the medication and switch to a lower-risk alternative. If the patient develops symptoms (palpitations, syncope), obtain urgent EKG, troponin, and cardiology evaluation regardless of QTc value.

Special Scenarios and Decision-Making

Scenario 1: Patient with Treatment-Resistant Schizophrenia Requires Clozapine, but Has Baseline QTc 480 ms

Clozapine has minimal QT-prolonging effects; it is not on the high-risk list despite REMS monitoring for other reasons (agranulocytosis). Proceeding with clozapine is reasonable; obtain baseline EKG, monitor cardiac symptoms, and recheck EKG at 4 weeks. The clinical benefit (clozapine's unique efficacy in TRS) likely outweighs modest QT prolongation risk from clozapine itself.

Scenario 2: Patient on Citalopram (20 mg/day) Requires Antipsychotic for New-Onset Psychosis; Options Are Ziprasidone or Quetiapine

Both ziprasidone and quetiapine have hERG blockade; using either with citalopram creates potential for additive QT prolongation (polypharmacy risk). Best option: Switch citalopram to sertraline (minimal cardiac risk) or fluoxetine (minimal cardiac risk), then start ziprasidone or quetiapine. Alternative: Discontinue citalopram, start antipsychotic only, reassess mood at 4 weeks. Least ideal: Continue citalopram + ziprasidone while obtaining baseline EKG, frequent monitoring, and accepting elevated torsades risk.

Scenario 3: Female Patient Age 72 with Anorexia Nervosa, HR 48 bpm, K+ 3.1 mEq/L, Requires Treatment for Severe Depression

This patient has maximal cardiac risk (female, older age, eating disorder, bradycardia, hypokalemia). Any QT-prolonging antidepressant (citalopram, escitalopram, TCAs) carries extreme torsades risk. Best approach: (1) Aggressively repleted potassium to >4.0 mEq/L, magnesium to >2.0 mg/dL; (2) Treat underlying eating disorder (nutritional rehabilitation); (3) Select sertraline or fluoxetine (minimal cardiac risk) for depression; (4) Obtain baseline and serial EKGs; (5) Coordinate care with medicine, cardiology, and eating disorder specialists. Only after cardiac stabilization and nutritional improvement should higher-risk antidepressants be considered.

Scenario 4: Patient on Ziprasidone (120 mg/day) for Schizophrenia Develops QTc 510 ms on Follow-Up EKG

QTc >500 ms is severely prolonged; risk of torsades is substantial. Management: (1) Check electrolytes urgently; if hypokalemia or hypomagnesemia present, repleted aggressively; (2) Obtain new EKG to confirm prolongation (exclude artifact); (3) Consider dose reduction of ziprasidone (from 120 to 80 mg/day) or switch to lower-risk antipsychotic (aripiprazole, risperidone, olanzapine); (4) If antipsychotic efficacy was good at 120 mg/day, consider brief hospitalization for cardiac monitoring during transition to alternative agent; (5) Cardiology referral for EKG interpretation and risk assessment; (6) Once on alternative agent, recheck EKG at 4 weeks to confirm QTc improvement.